Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response. [More]
'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells. [More]
UC Irvine scientist receives New Innovator Award to create stem cell-based treatments for cancer

UC Irvine scientist receives New Innovator Award to create stem cell-based treatments for cancer

UC Irvine scientist Weian Zhao will receive a prestigious National Institutes of Health Director's New Innovator Award to further his efforts to create stem cell-based detection methods and treatments for cancer. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
FDA grants orphan drug designation for neuroblastoma vaccine

FDA grants orphan drug designation for neuroblastoma vaccine

The U.S. Food and Drug Administration granted orphan drug designation for a neuroblastoma vaccine from MabVax Therapeutics, providing development incentive with market exclusivity of the novel treatment for children with this deadly childhood cancer. [More]

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration. [More]
IRCM researchers discover mechanism that promotes progression of medulloblastoma

IRCM researchers discover mechanism that promotes progression of medulloblastoma

Scientists at the IRCM discovered a mechanism that promotes the progression of medulloblastoma, the most common brain tumour found in children. The team, led by Fr-d-ric Charron, PhD, found that a protein known as Sonic Hedgehog induces DNA damage, which causes the cancer to develop. [More]
Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014. [More]
State highlights: Fla. toughens drug compounding laws; Conn. hospitals leave largest insurer

State highlights: Fla. toughens drug compounding laws; Conn. hospitals leave largest insurer

A selection of health policy stories from Florida, Connecticut, New York, Michigan, Louisiana, Pennsylvania and Arkansas. [More]
Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients. [More]

Majority of cancer survivors not financially prepared for cancer diagnosis, treatment

The majority (62%) of America's middle-income cancer survivors say they were not financially prepared for cancer diagnosis and treatment, according to a new study released by the Washington National Institute for Wellness Solutions. [More]
CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy. [More]
Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events. [More]
Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid. [More]
Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. [More]
Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
New approach to solve global challenges in food security, emerging diseases and biodiversity loss

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]